Arsenakis M, May J T
Infect Immun. 1981 Jul;33(1):22-8. doi: 10.1128/iai.33.1.22-28.1981.
Sera collected from confirmed herpes simplex virus type 2 (HSV-2) patients were found to be devoid of complement-fixing antibody to the AG-4 antigen at the time of the herpes lesion outbreak in 10 out of 13 cases. However, 1 to 4 weeks after HSV-2 lesion appearance, 28 out of 30 patients acquired complement-fixing antibody to the AG-4 antigen. The sera of these patients contained immunoglobulin M antibody activity and the ability to immunoprecipitate a 160,000-molecular weight early HSV-2 antigen (the AG-4 antigen). Also, these sera were used to show that a variety of anti-herpes virus compounds had a negligible effect on AG-4 production in HSV-2-infected HEp-2 cells. The majority of the compounds tested (including acycloguanosine and phosphonoformate) are known to inhibit late antigen production, suggesting that the AG-4 antigen is an early antigen. It is probably an immediate early antigen (alpha) as it is formed in the presence of cycloheximide and actinomycin D, a treatment which is used to accumulate alpha proteins.
在13例单纯疱疹病毒2型（HSV - 2）确诊患者中，有10例在疱疹病灶发作时采集的血清被发现缺乏针对AG - 4抗原的补体结合抗体。然而，在HSV - 2病灶出现后的1至4周，30例患者中有28例获得了针对AG - 4抗原的补体结合抗体。这些患者的血清含有免疫球蛋白M抗体活性以及免疫沉淀160,000分子量早期HSV - 2抗原（AG - 4抗原）的能力。此外，这些血清被用于表明多种抗疱疹病毒化合物对HSV - 2感染的HEp - 2细胞中AG - 4的产生影响可忽略不计。所测试的大多数化合物（包括阿昔洛韦和膦甲酸盐）已知可抑制晚期抗原的产生，这表明AG - 4抗原是一种早期抗原。它可能是一种即刻早期抗原（α），因为它是在放线菌酮和放线菌素D存在的情况下形成的，这种处理用于积累α蛋白。
